MX2022003585A - Metodos para tratar hiperfenilalaninemia. - Google Patents

Metodos para tratar hiperfenilalaninemia.

Info

Publication number
MX2022003585A
MX2022003585A MX2022003585A MX2022003585A MX2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A
Authority
MX
Mexico
Prior art keywords
methods
hyperphenylalaninemia
treating
treating hyperphenylalaninemia
sepiapterin
Prior art date
Application number
MX2022003585A
Other languages
English (en)
Inventor
Niel Smith
Original Assignee
Ptc Therapeutics Mp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc filed Critical Ptc Therapeutics Mp Inc
Publication of MX2022003585A publication Critical patent/MX2022003585A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención presenta métodos para reducir la concentración de fenilalanina en sangre en un sujeto por la administración de sepiapterina, o una sal farmacéuticamente aceptable de la misma.
MX2022003585A 2019-09-25 2020-09-25 Metodos para tratar hiperfenilalaninemia. MX2022003585A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962905720P 2019-09-25 2019-09-25
PCT/US2020/052871 WO2021062264A1 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia

Publications (1)

Publication Number Publication Date
MX2022003585A true MX2022003585A (es) 2022-04-19

Family

ID=72827023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003585A MX2022003585A (es) 2019-09-25 2020-09-25 Metodos para tratar hiperfenilalaninemia.

Country Status (12)

Country Link
US (1) US20220362249A1 (es)
EP (1) EP4034122A1 (es)
JP (1) JP2022549834A (es)
KR (1) KR20220070477A (es)
CN (1) CN114650825A (es)
AU (1) AU2020353676A1 (es)
BR (1) BR112022003719A2 (es)
CA (1) CA3150003A1 (es)
IL (1) IL291565A (es)
JO (1) JOP20220042A1 (es)
MX (1) MX2022003585A (es)
WO (1) WO2021062264A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301470A (en) 2016-11-29 2023-05-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CN112703002A (zh) 2018-05-30 2021-04-23 Ptc医疗Mp公司 增加墨蝶呤血浆暴露的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
EP2926805B1 (en) * 2014-03-31 2016-05-18 Vasopharm GmbH Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
IL301470A (en) 2016-11-29 2023-05-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
MX2020002271A (es) * 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
WO2019232120A1 (en) 2018-05-30 2019-12-05 Censa Pharmaceuticals Inc. Pharmaceutically acceptable salts of sepiapterin

Also Published As

Publication number Publication date
AU2020353676A1 (en) 2022-04-14
IL291565A (en) 2022-05-01
BR112022003719A2 (pt) 2022-05-31
US20220362249A1 (en) 2022-11-17
CA3150003A1 (en) 2021-04-01
KR20220070477A (ko) 2022-05-31
EP4034122A1 (en) 2022-08-03
WO2021062264A1 (en) 2021-04-01
CN114650825A (zh) 2022-06-21
JP2022549834A (ja) 2022-11-29
JOP20220042A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
ZA202202097B (en) Amino pyrimidine ssao inhibitors
JOP20220042A1 (ar) طرق لعلاج فرط فينيل ألانين الدم
CY1124789T1 (el) Πυριμιδιν-2-υλαμινο-1η-πυραζολια ως αναστολεις lrrk2 για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
SG10201902598VA (en) Peptidomimetic macrocycles and formulations thereof
NZ739503A (en) A novel approach for treatment of cancer using immunomodulation
MX2018003657A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan el adn e inhibidores de proteina relacionada con ataxia telangiectasia y rad3 (atr).
MX2022006663A (es) Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
MX2020002271A (es) Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
PH12019502197A1 (en) Macrocyclic compound and uses thereof
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2018013271A (es) Compuestos 9-aminometil minociclina y metodos para utilizarlos en el tratamiento de infeccion de vias urinarias (ivu).
PH12016501751A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
EA202092540A1 (ru) Комбинации для лечения рака
PH12019501566A1 (en) Amide compounds and use thereof
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2022005951A (es) Compuestos de pirrolotriazina que actuan como inhibidor de mnk.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2019004602A (es) Agentes anti-proliferativos para tratar pah.
MX2019005070A (es) Compuestos de 9-aminometil minociclina y su uso en el tratamiento de neumonía bacteriana adquirida en la comunidad (cabp).
MX2021012824A (es) Métodos para tratar el prurito.
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX2022000729A (es) Terapia de combinacion para el tratamiento del cancer.